The Renal Handling of Parathyroid Hormone

ROLE OF PERITUBULAR UPTAKE AND GLOMERULAR FILTRATION

KEVIN J. MARTIN, KEITH A. HRUSKA, JANE LEWIS, CHARLES ANDERSON, and
EDUARDO SLATOPOLSKY, Renal Division, Department of Internal
Medicine, and Department of Surgery, Washington University School
of Medicine, St. Louis, Missouri 63110

ABSTRACT

The mechanisms of uptake of parathyroid hormone (PTH) by the kidney was studied in anesthetized dogs before and after ureteral ligation. During constant infusion of bovine PTH (b-PTH 1-84), the renal arteriovenous (A-V) difference for immunoreactive PTH (i-PTH) was 22±2%. After ureteral ligation and no change in renal plasma flow, A-V i-PTH fell to 15±1% (P < 0.01), indicating continued and significant uptake of i-PTH at peritubular sites and a lesser role of glomerular filtration (GF) in the renal uptake of i-PTH. Since, under normal conditions, minimal i-PTH appears in the final urine, the contribution of GF and subsequent tubular reabsorption was further examined in isolated perfused dog kidneys before and after inhibition of tubular reabsorption by potassium cyanide. Urinary i-PTH per 100 ml GF rose from 8±4 ng/min (control) to 170±45 ng/min after potassium cyanide. Thus, i-PTH is normally filtered and reabsorbed by the tubular cells. The physiological role of these two mechanisms of renal PTH uptake was examined by giving single injections of b-PTH 1-84 or synthetic b-PTH 1-34 in the presence of established ureteral ligation. After injection of b-PTH 1-84, renal A-V i-PTH was 20% only while biologically active intact PTH was present (15–20 min). No peritubular uptake of carboxy terminal PTH fragments was demonstrable. In contrast, after injection of synthetic b-PTH 1-34, renal extraction of N-terminal i-PTH after ureteral ligation (which was 13.4±0.6% vs. 19.6±0.9% in controls) continued for as long as i-PTH persisted in the circulation. These studies indicate that both GF and peritubular uptake are important mechanisms for renal PTH uptake. Renal uptake of carboxy terminal fragments of PTH is dependent exclusively upon GF and tubular reabsorption, whereas peritubular uptake can only be demonstrated for biologically active b-PTH 1-84 and synthetic b-PTH 1-34.

INTRODUCTION

Previous studies from this laboratory have shown that after a single injection of bovine parathyroid hormone (b-PTH 1-84) to dogs, the kidney extracted 20% of delivered carboxy terminal (COOH) terminal immunoreactivity, while the circulating species of immunoreactive parathyroid hormone (i-PTH) changed from intact hormone to a heterogeneous mixture of intact hormone and COOH terminal fragments, and finally to only COOH terminal fragments (1). In contrast, the liver demonstrated selective uptake of intact parathyroid hormone (PTH) and no demonstrable uptake of PTH fragments (2). These observations suggested that the mechanisms of uptake of i-PTH by liver and kidney are different; furthermore, the kidney possesses an uptake mechanism specific for the biologically inactive COOH-terminal fragments of PTH.

Studies in vitro have shown PTH activation of adenylyl cyclase in membranes obtained from the peritubular side of the cell (3, 4). Since binding of labeled PTH to these membranes has been demonstrated (3, 5), it is possible that uptake of PTH by receptors on the peritubular membrane account for the renal extraction of i-PTH seen in our studies. On the other hand, PTH has a mol wt of 9,500 and therefore should be ultrafilterable at the level of the glomerulus. Autoradiographic evidence has shown labeled PTH in the proxi-

---

*Abbreviations used in this paper: A-V, arteriovenous; COOH terminal, carboxy terminal; ICG, indocyanine green; KCN, potassium cyanide; PAH, para-aminophenol; PTH, parathyroid hormone; b-PTH 1-84, bovine PTH; i-PTH, immunoactive PTH; syn-b-PTH 1-34, biologically active synthetic N-terminal fragment of bovine PTH.*

This work was presented, in part, at the American Federation of Clinical Research, Chicago, Ill., November 1976.

Dr. Martin is a recipient of a fellowship from the National Kidney Foundation.

Received for publication 28 January 1977 and in revised form 6 June 1977.
mal tubule (6), although minimal immunoreactive PTH appears in the final urine (1, 7). Thus, the possibility that glomerular filtration and subsequent reabsorption and degradation by the tubular cells also plays a role in the renal uptake of i-PTH must be considered. This type of mechanism has been described for other low molecular weight proteins such as lysozyme (8), insulin (9), and glucagon (10).

The present studies were designed to examine the relative roles of peritubular uptake and glomerular filtration in the renal handling of PTH in vivo.

**METHODS**

**Preparation of dogs for studies in vivo.** Studies were performed under pentobarbital anesthesia (30 mg/kg) on 12 mongrel dogs weighing 18–25 kg. Through a mid-line abdominal incision a polyethylene catheter was inserted into the left renal vein, and both ureters were catheterized. In two animals, a 23-gauge needle was placed in the left renal artery for infusion of indocyanine green. The catheters were brought out through stab wounds in the flanks and the incision closed. A femoral artery was catheterized for blood sampling and a jugular vein catheter was placed for infusion of solutions.

**Study protocol.** After priming doses of creatinine (50 mg/kg) and para-aminohippurate (PAH) (4 mg/kg) were given, a constant infusion of 0.9% NaCl containing creatinine and PAH at 2.5 ml/min was begun, so as to maintain plasma concentrations of 9–10 mg/100 ml and 1–2 mg/100 ml for creatinine and PAH, respectively. Two groups of dogs were studied. The first group (five dogs) was given a constant infusion of purified b-PTH 1–84 in 0.9% NaCl containing 10% canine plasma at the rate of 150–200 ng/min with a Harvard syringing pump (Harvard Apparatus Co., Inc., Millis, Mass.). After a 90-min equilibration period, three control periods were obtained for creatinine clearance, renal plasma flow, and arteriovenous (A-V) difference across the kidney for creatinine and i-PTH. The left ureteral catheter was then clamped, and when the A-V creatinine difference across the kidney approached zero, three to six experimental periods were obtained to determine A-V difference for i-PTH across the kidney. Renal plasma flow during ureteral obstruction was measured by electromagnetic flow-meter (three dogs) or by dye dilution techniques (two dogs) with an infusion of indocyanine green (ICG) (Hyson, Westcott, and Dunning, Inc., Baltimore, Md.) into the renal artery.

The second group of seven dogs received a single injection (5 µg/kg) of b-PTH 1–84 (three dogs), or synthetic b-PTH (syn-b-PTH 1–34) (four dogs) in the presence of established ureteral obstruction (A-V creatinine difference less than 5%). Blood samples for A-V difference of i-PTH across the kidney were obtained at intervals of 2–5 min for 60–90 min after injection of PTH.

**Studies on isolated perfused kidneys.** Kidneys from mongrel dogs were perfused with fresh heparinized autologous blood diluted 4:1 with 0.9% NaCl at 37°C on a Waters MOX 100 kidney perfusion apparatus (Waters Instruments Inc., Rochester, Minn.) as previously described (11). Purified b-PTH 1–84 was infused into the perfusion circuit at 200 ng/min. Urinary losses of fluid and electrolytes were replaced with 0.45% NaCl containing creatinine and PAH to maintain their concentrations in the perfusate. After three control periods, potassium cyanide (KCN) was added to the perfusate to a final concentration of 3 mM and further clearance periods collected.

**Studies in the rat.** To examine the relative roles of renal plasma flow and glomerular filtration on PTH uptake in a second species, female Holtzman rats weighing 300–350 g were studied under pentobarbital anesthesia (50 mg/kg i.p.) 60 min after bilateral ureteral ligation (five rats); bilateral nephrectomy (four rats); or sham operation (four rats). A single injection of syn-b-PTH 1–34 (10 µg/100 g body wt) was administered through a jugular vein catheter and blood samples drawn from a carotid artery cannula at 3, 20, and 60 min after injection. Blood volume was replaced by administering an equal volume of 0.9% NaCl.

**Source of PTH.** Highly purified b-PTH 1–84 was obtained from Inolex Corp., Biomedical Div., Glenwood, Ill. (sp act 900–1,500 u/mg in a rat bioassay). syn-b-PTH 1–34 was obtained from Beckman Instruments, Inc., Spincio Div., Palo Alto, Calif. (sp act 3,700 U/mg in a renal adenylyl cyclase system).

**Chemical determinations.** Creatinine was measured by the Jaffe reaction as described by Folin (12) and adapted for the Technicon AutoAnalyzer (Technicon Instruments Corp., Tarrytown, N. Y.). PAH was measured by the method of Harvey and Brothers (13) as adapted for the Technicon AutoAnalyzer. ICG was measured as described previously (2).

**Radioimmunoassay methods.** Plasma levels of i-PTH after injection of b-PTH 1–84 and syn-b-PTH 1–34 were measured as described previously (1, 2). In the present studies antiserum CH9, which reacts primarily with carboxyl determinants (1), was used in a final dilution of 1:80,000 and antiserum CH9N, which is specific for the synthetic amino terminal fragment of b-PTH (1), was used in a final dilution of 1:25,000. Endogenous canine PTH was subtracted as a background from all samples (normal range 0.1–0.45 ng b-PTH eq/ml).

For assay of i-PTH in the urine obtained from the isolated perfused kidneys, appropriate controls for nonspecific binding, tracer binding, and standard curves were performed with urine from a control isolated, perfused kidney at volumes identical to the unknown urine assayed for i-PTH. Effects of KCN on the assay system were likewise evaluated. The effect of these additions on the radioimmunoassay was insignificant.

**Calculations.** Renal plasma flow (PTH) was calculated with the Wolff modification of the Fick principle (14). Renal plasma flow with ICG was determined by dividing the infusion rate of ICG by the difference between the ICG concentration in renal vein and aorta. Extraction of creatinine or i-PTH by the kidney was determined by the A-V difference across the kidney divided by the arterial creatinine or i-PTH concentration. Statistical analysis of paired or nonpaired data was performed with the Student’s t test.

**RESULTS**

Studies during constant infusion of b-PTH 1–84 are shown in Table I and Fig. 1. Renal plasma flow averaged 138±18 ml/min in the control periods and 143±24 ml/min after ureteral obstruction. These values are not significantly different from each other. Creatinine extraction by the kidney decreased from 20±2% to 4±1% after ureteral obstruction. On the other hand, mean extraction for i-PTH fell from 22±2% in control to 15±1% in the experimental periods (P < 0.01). Thus, the kidney continues to extract i-PTH from the circulation when the glomerular
filtration rate is decreased by ureteral obstruction during constant infusion of b-PTH 1-84. However, the reduction in the A-V difference for i-PTH after ureteral obstruction compared to control presumably indicates that a fraction of the renal i-PTH uptake is due to glomerular filtration.

Studies in the isolated perfused kidney. To further examine the role of glomerular filtration and tubular reabsorption in the renal removal of i-PTH from the circulation, studies were performed in isolated perfused dog kidneys, before and after inhibition of tubular reabsorption by the addition of 3 mM KCN to the perfusate. The results of three such experiments are shown in Table II and Fig. 2. KCN decreased creatinine clearance from 28.2±3.8 ml/min to 10.5

### Table I

<table>
<thead>
<tr>
<th>Dog no.</th>
<th>C</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ml/min</td>
<td>ml/min</td>
</tr>
<tr>
<td>1</td>
<td>27</td>
<td>120</td>
</tr>
<tr>
<td>2</td>
<td>18</td>
<td>89</td>
</tr>
<tr>
<td>3</td>
<td>23</td>
<td>160</td>
</tr>
<tr>
<td>4</td>
<td>31</td>
<td>125</td>
</tr>
<tr>
<td>5</td>
<td>27</td>
<td>196</td>
</tr>
</tbody>
</table>

Mean: 25 | 138 | 143 | 20 | 4 | 22 | 15|

SEM: 4 | 18 | 24 | 2 | 1 | 2 | 1|

P – | NS | <0.001 | <0.01|

C<sub>cr</sub>, exogenous creatinine clearance; RPF, renal plasma flow; creatinine extr., arteriovenous creatinine difference divided by arterial creatinine concentration x 100; i-PTH extr., percent extraction of immunoreactive PTH. C = control; E = experimental. Statistical analysis by paired t test.

### Table II

<table>
<thead>
<tr>
<th>Exp. no.</th>
<th>C&lt;sub&gt;cr&lt;/sub&gt;</th>
<th>Arterial i-PTH</th>
<th>Urine i-PTH</th>
<th>C&lt;sub&gt;sa&lt;/sub&gt; / C&lt;sub&gt;cr&lt;/sub&gt; x 100</th>
<th>Urine i-PTH / C&lt;sub&gt;cr&lt;/sub&gt; x 100</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C</td>
<td>E</td>
<td>C</td>
<td>E</td>
<td>C</td>
</tr>
<tr>
<td>P</td>
<td>ml/min</td>
<td>ng/ml</td>
<td>ng/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>35.0</td>
<td>8.1</td>
<td>9.6</td>
<td>12.9</td>
<td>0.6</td>
</tr>
<tr>
<td>2</td>
<td>22.0</td>
<td>10.2</td>
<td>4.9</td>
<td>5.3</td>
<td>3.3</td>
</tr>
<tr>
<td>3</td>
<td>27.5</td>
<td>13.1</td>
<td>5.6</td>
<td>6.6</td>
<td>2.5</td>
</tr>
<tr>
<td>Mean</td>
<td>28.2</td>
<td>10.5</td>
<td>6.7</td>
<td>8.3</td>
<td>2.1</td>
</tr>
<tr>
<td>SEM</td>
<td>3.8</td>
<td>1.5</td>
<td>1.5</td>
<td>2.4</td>
<td>0.8</td>
</tr>
</tbody>
</table>

C<sub>cr</sub>, exogenous creatinine clearance; arterial i-PTH, arterial immunoreactive PTH concentration; Urine i-PTH, urine flow rate multiplied by urinary i-PTH concentration: C<sub>sa</sub> / C<sub>cr</sub> x 100, clearance of sodium divided by clearance of creatinine x 100; Urine i-PTH / C<sub>cr</sub> x 100, urinary excretion of i-PTH per 100 ml glomerular filtration rate. C = Control; E = experimental.
conditions is creatinine A-V presence 1-34.

The pattern of renal extraction of i-PTH after injection of b-PTH 1-84 (assayed with antisera CH9) is shown in Fig. 3. Extraction of i-PTH after injection of b-PTH 1-84 was 20±2% for 15 min after injection and then fell to zero. No further extraction was seen up to 60 min after injection, in spite of persisting high levels of i-PTH in the circulation (2-5 ng/ml).

In contrast, after a single injection of the biologically active synthetic N-terminal fragment of bovine PTH (syn-b-PTH 1-34), extraction by the obstructed kidney was constant (mean 13.4±0.06%) until immunoreactively disappeared from the circulation (90 min postinjection). These studies are portrayed in Fig. 4 compared with the extraction of immunoreactivity by the normal kidney (mean 19.6±0.9%). PTH extraction by the obstructed kidney was significantly reduced compared with the normal kidney (P < 0.001), presumably indicating the contribution of glomerular filtration to the renal uptake of this PTH fragment.

Studies in the rat. The studies on the effect of ureteral obstruction on the renal uptake of syn-b-PTH 1-34 were extended to another species, the rat, and compared with the effect of bilateral nephrectomy. The disappearance of N-terminal immunoreactivity from plasma was studied in three groups of rats after a single injection of syn-b-PTH 1-34 given 1 h after bilateral ureteral ligation, bilateral nephrectomy, or sham operation (Fig. 5). Radioimmunoassay utilized antiserum CH9N (see Methods). Disappearance of
immunoreactivity was slightly, although significantly delayed in the bilateral ureteral ligation group (P < 0.05), indicating the role of glomerular filtration on the renal uptake of syn-b-PTH 1-34. The bilaterally nephrectomized group, however, demonstrated marked delay in the disappearance of immunoreactivity (P < 0.001) compared with the sham (normal) or bilateral ureteral ligation groups, indicating the importance of peritubular uptake in the clearance of this biologically active synthetic N-terminal fragment of bovine PTH.

**DISCUSSION**

Previous studies from this laboratory have demonstrated the importance of the kidney in the removal of immunoreactive PTH from the circulation (1). Additional studies of the uptake of PTH by the liver demonstrated selective uptake of the intact hormone and no uptake of PTH fragments by this organ (2), whereas the kidney could extract all immunoreactive species of PTH. Uptake of the (biologically inactive) carboxyl terminal fragments of PTH by the kidney suggested that there may be more than a single mechanism of uptake of i-PTH by this organ. The present studies were designed to evaluate the roles of peritubular uptake and glomerular filtration in the uptake of immunoreactive PTH by the kidney.

The principle technique used in these studies employed ureteral obstruction to reduce glomerular filtration and preserve renal plasma flow. Although low values of glomerular filtration may persist in the presence of ureteral obstruction in this model, and as much as 25% of filtered creatinine may be reabsorbed under conditions of increased intratubular pressure (15), the marked reduction in creatinine extraction from 20±2% in control to 4±1% after ureteral obstruction indicates a substantial reduction in glomerular filtration rate.

The initial studies, Table I and Fig. 1, performed during a constant infusion of b-PTH 1-84, examined the A-V difference of i-PTH across the kidney before and after ureteral obstruction. Renal extraction of i-PTH decreased from 22.0±2% in the control periods to 15.0±1% after ureteral obstruction. These results demonstrate that although the reduction in glomerular filtration rate caused by ureteral obstruction is associated with a fall in the renal extraction of i-PTH, significant extraction of i-PTH persists which presumably relates at least in part to uptake of i-PTH at peritubular sites.

Previous studies have shown that only small amounts of immunoreactive PTH appear in the final urine under normal conditions (1, 7). However, the possibility that PTH is filtered and subsequently reabsorbed by the tubular cells remains a possibility. This possible mechanism of renal PTH uptake was examined in the isolated perfused dog kidney after inhibition of tubular reabsorption with KCN as previously described in studies designed to examine the renal handling of lysozyme (8). After inhibition of tubular reabsorption, absolute urinary excretion of i-PTH increased more than sixfold (Table II and Fig. 2), indicating that i-PTH is being filtered at the glomerulus and is reabsorbed by the tubular cells under normal conditions. The increase in urinary excretion of i-PTH after inhibition of tubular reabsorption is of even greater magnitude (20-fold) if the decrease in creatinine clearance after the addition of KCN is considered. True fractional excretion of i-PTH was not calculated since preliminary studies in our laboratory indicate that approximately 30% of intact PTH is bound to plasma proteins (unpublished results) and therefore may not all be ultrafilterable at the level of the glomerulus. Furthermore, it is not known if the immunoreactive fragments of PTH share the same protein binding characteristics as intact hormone. In addition, because of the immunoheterogeneity of circulating PTH both in the intact animal (1, 2) and in the isolated perfused kidney (11), it is unlikely that the different immunoreactive fragments of PTH of different molecular weights would have the same sieving coefficients. Thus, the calcula-
tions of true ultrafilterable i-PTH is not possible at the present time.

The use of single injections of b-PTH 1-84 in the presence of established ureteral obstruction (Fig. 3) provided a means of evaluating the peritubular uptake of i-PTH as the circulating species of i-PTH changed from predominantly intact hormone to a heterogeneous mixture of intact hormone and its fragments and finally to COOH terminal fragments alone (1, 2). We have shown previously that intact PTH is rapidly cleared from the circulation after single injection of b-PTH 1-84 and that 15–25 min after injection circulating i-PTH consists only of COOH terminal fragments (2). The results of such studies in three animals (Fig. 3) show that the obstructed kidney extracts i-PTH for 15–20 min after a single injection of b-PTH 1-84, and no further extraction could be demonstrated during the next 90 min in spite of persisting high levels of i-PTH in the circulation (2–5 ng/ml). These studies show that renal extraction of i-PTH by the obstructed kidney only occurs when biologically active intact hormone is present in the circulation. Thus, after a single injection of b-PTH 1-84 the nonfiltering kidney appears to demonstrate selective uptake of intact PTH and no uptake of the biologically inactive C-terminal i-PTH fragments. This selective uptake of intact hormone is similar to PTH uptake by the liver seen in our previous studies (2). However, after single injection of the biologically active synthetic N-terminal fragment of b-PTH (syn b-PTH 1-34) in the presence of established ureteral obstruction (Fig. 4), the obstructed kidney continued to extract N-terminal immunoreactivity after a single injection of syn b-PTH 1-34 until immunoreactivity disappeared from the circulation. The mean extraction by the obstructed kidney (13.4 ± 0.6%) was less than that of normal kidneys (19.6 ± 0.9%) and can be attributed to the contribution of glomerular filtration to the renal extraction of N-terminal immunoreactivity under normal conditions. The continued extraction of N-terminal immunoreactivity by the obstructed kidney is presumably related to uptake of this biologically active PTH fragment at peritubular sites. This observation suggests that the receptors of the kidney differ from those in the liver, since no hepatic uptake of syn-b-PTH 1-34 was demonstrable in our previous studies (2).

The relative roles of peritubular uptake and glomerular filtration in the renal uptake of biologically active PTH were evaluated in the rat by comparing the disappearance of N-terminal immunoreactivity in normal rats, in rats after bilateral ureteral ligation and in bilaterally nephrectomized rats, after a single injection of syn b-PTH 1-34 (Fig. 5). Plasma disappearance of i-PTH was somewhat delayed in the bilateral ureteral ligation group (P < 0.05), but was markedly prolonged in the bilaterally nephrectomized group (P < 0.001), indicating the major role of peritubular uptake of this biologically active fragment of PTH.

Thus, the present studies demonstrate that two mechanisms exist for the renal removal of i-PTH from the circulation (Fig. 6). Uptake of biologically inactive PTH fragments appears to be dependent upon glomerular filtration and reabsorption and degradation by the tubular cells. On the other hand, peritubular uptake can only be demonstrated for the biologically active intact hormone and its biologically active synthetic N-terminal fragment. The present results differ from recent studies on the renal handling of 125I-b-PTH by the kidney. In these preliminary studies glomerular filtration and tubular reabsorption was felt to be the principle renal mechanism for PTH uptake (16). However, these studies may be reconciled with the present results in view of the fact that PTH iodinated by the chloramine-T method is biologically inactive and does not bind specifically to renal cortical membranes in vitro (17). Thus, the renal uptake of the biologically inactive 125I-b-PTH may be analogous to the renal uptake of the biologically inactive PTH fragments seen in the present studies. That two mechanisms, i.e., peritubular uptake and glomerular filtration, are responsible for the renal uptake of PTH is not unique to this peptide and has previously been described for insulin, proinsulin and C-peptide (9), gastrin (18), and glucagon (10). The demonstration that the renal uptake of the biologically inactive fragments of i-PTH is dependent upon glomerular filtration, while the biologically active forms of i-PTH (intact b-PTH 1-84 and syn b-PTH 1-34) are handled mainly by peritubular uptake, could explain the marked accumulation of biologically inactive PTH fragments in patients with renal failure.

Renal Handling of Parathyroid Hormone 813

![Diagram](image_url)
ACKNOWLEDGMENTS

The authors thank Dr. Saulo Klahr for his critical review of this manuscript and Mrs. Patricia Verplancke for her secretarial assistance.

This investigation was supported by U. S. Public Health Service grants AM-05248, AM-09976, and AM-07126 from the National Institute of Arthritis, Metabolism, and Digestive Diseases.

REFERENCES


